Waystar Q3 2026: Strong Growth and Margins, but Premium Valuation Caps Upside

What happened

Waystar's Q3 2026 results show continued strong execution with revenue up 21% year over year to $325.6 million, net income of $31.0 million (10% margin), and adjusted EBITDA margin of 43%, reflecting operating leverage in its recurring revenue model. However, these results come a year after the company was already trading at a lofty valuation and carrying significant debt, as highlighted in the prior master report. While the growth and margins are impressive, investors should scrutinize the quality of earnings and whether the company has made progress on deleveraging and integration of acquisitions like Iodine. The press release focuses on non-GAAP metrics, and adjusted EBITDA margin of 43% suggests high profitability but may exclude meaningful expenses. Overall, the quarter supports the view that Waystar's business is strong, but the stock's risk-reward remains balanced given its premium valuation.

Implication

Investors should view Waystar's Q3 2026 results as evidence that the company's revenue model remains robust and that operating leverage is improving, with adjusted EBITDA margin reaching 43%. However, the reported net income margin of only 10% suggests that after accounting for full costs, profitability is more modest, and the company's high debt load from acquisitions like Iodine still poses a risk, especially if interest rates remain elevated. The press release highlights non-GAAP net income of $87.1 million, which is significantly higher than GAAP net income, so investors need to scrutinize adjustments for stock-based compensation and acquisition-related costs. Given that the master report previously flagged the stock as trading at a premium to its DCF-implied value and with high leverage, these results alone may not justify a more bullish stance unless valuation compresses or balance sheet improves. Therefore, maintaining a cautious stance appears appropriate, with close monitoring of deleveraging progress and integration synergies.

Thesis delta

The Q3 2026 results do not fundamentally alter the thesis; the company continues to execute well, but the valuation and leverage concerns from the master report remain unaddressed by this press release. While the strong revenue growth and high adjusted EBITDA margin are positive, the lack of detailed balance sheet data prevents confirmation of deleveraging, and the stock's premium multiple likely still embeds high expectations. Thus, the stance remains WAIT, pending either a more attractive entry price or clearer evidence of sustained profitability and debt reduction.